Unaudited Financial results for the quarter ended March 31, 2011

Sr. No Particulars 3 months ended March 31, 2011 3 months ended February 28, 2010 Rupees in Lakhs Previous Period from December 1, 2009 to December 31, 2010 (Audited)

(Unaudited)

(Unaudited)

3 4 5 6 7 8 9 10 11 12 13

14

Net Sales/ Income from Operations a Gross Sales Less: Excise Duty Net Sales b Other Operating Income Expenditure a Decrease/ (Increase) in Stock in Trade and Work-in-Progress b Consumption of Raw Materials c Purchase of Traded Goods d Employees Cost e Depreciation f Other Expenditure g Total Expenditure Profit from Operations before Other Income and Interest (1-2) Other Income Profit before Interest (3+4) Interest Profit before tax Tax Expenses (including current tax, deferred taxation and prior period adjustments for the period ) Net Profit for the period Paid- up Equity Share Capital (Face value of the share Rs. 10) Reserves excluding revaluation reserves (as per last audited balance sheet) Basic and diluted Earnings Per Share for the periods (not annualized) and for the previous period Rs. Public shareholding Number of Shares Percentage of Shareholding Promoters and promoter group shareholding a Pledged/ Encumbered Number of Shares Percentage of Shares (as a % of the total shareholding of promoter and promoter group) Percentage of Shares (as a % of the total share capital of the company) b Non - encumbered Number of Shares Percentage of Shares (as a % of the total shareholding of promoter and promoter group) Percentage of Shares (as a % of the total share capital of the company)

234,92 1,25 233,67 8,61 4,57 9,50 140,60 28,78 2,55 50,13 236,13 6,15 3,08 9,23 1 9,22 3,28 5,94 13,68

202,06 1,23 200,83 5,25 1,08 8,02 124,89 21,60 2,02 31,14 188,75 17,33 1,06 18,39 1 18,38 6,58 11,80 13,68

995,98 6,10 989,88 29,07 (25,08) 44,19 628,20 111,20 11,25 161,93 931,69 87,26 6,93 94,19 4 94,15 33,21 60,94 13,68 291,71 44.56

4.34

8.63

42,47,056 31.06%

42,47,056 31.06%

42,47,056 31.06%

94,28,184 100.00%

94,28,184 100.00%

94,28,184 100.00%

68.94%

68.94%

68.94%

Notes:
1. 2. The results for the quarter ended March 31, 2011 have been reviewed by the Audit Committee, approved by the Board of Directors and subjected to a Limited Review by the auditors of the Company, in compliance with Clause 41 of the Listing Agreement with Bombay Stock Exchange Limited. The members of the Company at their Annual General Meeting held on April 27, 2011, approved a dividend of Rs 17.00 per share on 1,36,75,240 equity shares of Rs 10.00 each value for the period December 1, 2009 to December 31, 2010, amounting to Rs 27,11 Lakhs (including Corporate Dividend Tax). The Company changed its accounting year from year ended November 30 to year ended December 31 from previous financial year onwards. Accordingly, the results for the current quarter are for three months ended March 31, 2011 and the previous quarter are for three months ended February 28, 2010. The results for the current quarter are therefore not comparable with those of the previous quarter. The Shareholders of the Company at the Court Convened meeting held on March 23, 2011 approved the Scheme of Amalgamation of Solvay Pharma India Limited with Abbott India Limited ("Scheme") pursuant to the provisions of Sections 391 to 394 and other applicable provisions of the Companies Act, 1956 and subject to approval of the Honorable High Court of Judicature at Bombay. The swap ratio for the merger is 2:3 i.e. every two shares of Solvay Pharma India Limited will entitle their holder to three shares of Abbott India Limited. Upon receipt of High Court approval, the Scheme would be effective January 1, 2011. .Accordingly the effect of the Scheme will be reflected in the financial results once all the statutory approvals are received. The Company continues to make significant strategic investments for expanding its field force to improve market coverage. The Company also continues to increase advertising and promotion efforts to capture market share and increase brand equity and patient/customer awareness. These initiatives are impacting the near term profitability.

3.

4.

5.

6. 7. 8.

The Company operates in one reportable business segment i.e. Pharmaceuticals and one reportable geographical segment i.e. Within India. There were no Investor Complaints pending at the beginning of the quarter. The Company received 4 complaints from the investors and 3 complaints have been resolved and disposed off during the quarter. There was 1 complaint lying unresolved at the end of the quarter. Figures for the prior period have been regrouped and/or reclassified wherever considered necessary.

For and on behalf of the Board,

Mr Vivek Mohan Managing Director Mumbai: Date: April 27, 2011